Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-19 4:05 pm Purchase | 2026-02-11 | 13G | Iveda Solutions, Inc. IVDA | Lind Global Fund III LP | 1,158,920 9.990% | 1,158,920 (New Position) | Filing History |
| 2026-02-17 4:06 pm Purchase | 2025-12-31 | 13G | Bionano Genomics, Inc. BNGO | Lind Global Fund III LP | 1,050,000 9.350% | 535,662 (+104.15%) | Filing History |
| 2026-02-04 4:31 pm Purchase | 2026-01-28 | 13G | Enveric Biosciences, Inc. ENVB | Lind Global Fund III LP | 141,265 9.990% | 141,265 (New Position) | Filing History |
| 2025-12-23 4:47 pm Purchase | 2025-12-18 | 13G | DEFSEC Technologies Inc. DFSC | Lind Global Fund III LP | 197,494 9.900% | 197,494 (New Position) | Filing History |
| 2025-11-14 4:09 pm Sale | 2025-09-30 | 13G | Silexion Therapeutics Ltd. SLXN | Lind Global Fund III LP | 212,500 6.400% | -11,550 (-5.16%) | Filing History |
| 2025-11-14 4:09 pm Sale | 2025-09-30 | 13G | Bionano Genomics, Inc. BNGO | Lind Global Fund III LP | 514,338 9.900% | -491,623 (-48.87%) | Filing History |
| 2025-09-24 8:00 pm Purchase | 2025-09-17 | 13G | Bionano Genomics, Inc. BNGO | Lind Global Fund III LP | 1,005,961 9.900% | 1,005,961 (New Position) | Filing History |
| 2025-09-18 5:47 pm Purchase | 2025-09-12 | 13G | Silexion Therapeutics Ltd. SLXN | Lind Global Fund III LP | 224,050 9.900% | 224,050 (New Position) | Filing History |